Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project.
Maria Pokorska-ŚpiewakAnna DobrzenieckaMałgorzata AniszewskaMagdalena MarczyńskaPublished in: Journal of clinical medicine (2021)
The results of this study confirm previous observations of a suitable efficacy and safety profile of LDV/SOF for the treatment of CHC genotypes 1 and 4 in adolescents.